Publication date: Aug 06, 2019
A Phase 1 clinical trial found T20K, Cyxone’s investigational plant protein-derived treatment for multiple sclerosis (MS), to be safe and well-tolerated in healthy men, and raising the possibility that it might work at low doses, the company announced. Preclinical studies showed that T20K works to lower the production of pro-inflammatory cytokines – signaling molecules that mediate inflammation – such as IL-2, and can effectively ease disease symptoms in animal models of MS. Results also noted that T20K, administered orally to the animals, had low toxicity and favorable pharmacokinetics (absorption, distribution, metabolism, and excretion in the body), suggesting that it may be a safe and effective therapy at low doses and with a low frequency of administration that might be every two weeks or monthly. Since this initial and very low dose of T20K showed a favorable pharmacokinetics profile, researchers did not need to study a planned second and higher dose, the company said in its release.
- Cyxone begins phase 1 trial of T20K for treatment of multiple sclerosis
- Cyxone announces positive results from phase I trial of T20K to treat multiple sclerosis
- Phase 1 Trial of T20K, Plant Protein-derived Therapy for MS, Doses 1st Group of Healthy Men
- Study to Compare GI Tolerability Following Oral Administration of Bafiertam™ or Tecfidera to Healthy Volunteers
- Phase 3 Trial of Ibudilast Planned for SPMS Patients with Inactive Disease, MediciNova Says
- Tecfidera Up Against Bafiertam in Phase 1 Study of GI Tolerability
- Cannabidiol-based Oral Treatment Seen to Promote Remyelination in Mice, Trial Planned in MS Patients
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-248
- Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial.